Anjul Agarwal
anjul_g@rediffmail.com
International Journal of PharmTech Research
IJPTR
0974-4304
2455-9563
10.20902/2017
http://www.sphinxsai.com/pharmtech.php
2019
12
01
In vitro Drug Release Prediction of Hydrochlorothiazide Modified Release Tablet using Wagner Nelson Method and Deconvolution Approach
Swapnil
Sharma
1
Sarvesh
Paliwal
1
Vikas D
Singhai
2
Department of Pharmacy, Banasthali Vidyapith, Banasthali, P.O.
Rajasthan-304022-India
Department of Pharmacy, Banasthali Vidyapith, Banasthali, P.O.
Rajasthan-304022-India
2019
49
56
120107
10.20902/IJPTR.2019.120107
http://dx.doi.org/10.20902/IJPTR.2019.120107
Background: Immediate release formulation of Hydrochlorothiazide is available in
market. Cmax achieved at 2 h, duration of action persist for 6-12 h, resulting in multiple dosing
to maintain plasma concentration and in vivo activity. Objective: The objective of research
work was to design modified release tablets of Hydrochlorothiazide 25 mg with the intention of
once a day dosing. Cmax will achieve after 10 to 12 h of administration. This controlled release
will constantly induce diuretic activity for whole night and day especially during early morning
hours, resulting in decreased blood volume, reduced cardiac output and controlled blood
pressure. When patient awakes up in morning, blood pressure will be comparatively low thus
reducing the frequency of cardiac arrest.Method: Here an attempt has been made to kinetically
calculate required in-vitro dissolution profile by deconvolution method using Wagner–nelson
equation. Plasma concentration time profile of immediate release tablet 12.5 mg is available in
literature and that of modified release formulation 25 mg is calculated such that Area under
curve of modified release tablet matches with that of two immediate release tablets of 12.5 mg
along with Cmax and Kel, thus meeting the criteria for bio-equivalency. Tmax will be delayed
from 2 h to approximately 10 h. Results: In-vivo dissolution profile is calculated from the
equation of “fraction of drug absorbed”. Perfect IVIVC is matched when value of slope is 1,
intercept is 0 and correlation coefficient (R2) 0.99. Conclusion: This in-vitro profile will be
used further to develop modified release formulation
http://sphinxsai.com/2019/ph_vol12_no1/1/(49-56)V12N1PT.pdf
Area under curve
Cmax
Elimination rate constant
Deconvolution
Wagner Nelson equation
IVIVC
British Medical Journal
Wroe SJ, Sandercock P, Bamford J, Dennis M, Slattery J, Warlow C
304
155
1992
10.1136/bmj.304.6820.155
https://doi.org/10.1136/bmj.304.6820.155
The New England Journal of Medicine
Tofler GH, Brezinski D, Schafer AI, Czeisler CA, Rutherford JD, Willich SN et al.
316
1514
1987
10.1056/NEJM198706113162405
https://doi.org/10.1056/NEJM198706113162405
Current
Problems in Cardiology
Wolk R, Gami AS, Garcia-Touchard A, Somers VK
30
625
2005
10.1016/j.cpcardiol.2005.07.002
https://doi.org/10.1016/j.cpcardiol.2005.07.002
Circulation
Lampert R, Rosenfeld L, Batsford W, Lee F, McPherson C
90
241
1994
10.1161/01.CIR.90.1.241
https://doi.org/10.1161/01.CIR.90.1.241
American Heart
Journal
Guo YF, Stein PK
145
779
2003
10.1016/S0002-8703(02)94797-6
https://doi.org/10.1016/S0002-8703(02)94797-6
AmericanJournal of Cardiology
Andreotti F, Davies GJ, Hackett DR, Khan MI, De Bart AC, Aber VR et al.
62
635
1988
10.1016/0002-
9149(88)90669-8
https://doi.org/10.1016/0002-
9149(88)90669-8
American Journal of Cardiology
Willich SN, Levy D, Rocco MB, Tofler GH, Stone PH, Muller JE
60
801
1987
10.1016/0002-9149(87)91027-7
https://doi.org/10.1016/0002-9149(87)91027-7
The seventh report of the joint national committee on Prevention, Detection, Evaluation and Treatment
of high blood pressure. U.S. Department of health and human services. August 2004
2017 Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in
Adults. A report of the American College of Cardiology/American Heart Association Task Force on
Clinical Practice Guidelines
PRESCRIBING INFORMATION: PrUROZIDE (Hydrochlorothiazide, USP) 25, 50, and 100 mg
Tablets; Date of revision: January 16, 2013
PRODUCT MONOGRAPH: PRAPO-HYDRO Hydrochlorothiazide Tablets USP 12.5 mg; Date of
revision: April 4, 2014
Journal of bioequivalence & bioavailability
Sakore S, Chakraborty B
S3
1
2011
Gibaldi, M, Perrier D. Pharmacokinetics. 2nded. Marcel Dekker: New York 1982
Arzneimittel
Forschung
Niopas I, Daftsios AC, Nikolaidis N
54
160
2004
Product Monograph. PrMINT-HYDROCHLOROTIAIZDE (Hydrochlorothiazide Tablet USP 12.5 mg)
Journal of Pharmaceutical Sciences
Wagner JG, Nelson E
52
610
1963
Journal of Pharmaceutical and Biomedical Analysis
Shah JV, Parekh JM, Shah PA, Shah PV, Sanyal M, Shrivastav PS
7
309
2017
10.1016/j.jpha.2017.06.001
https://doi.org/10.1016/j.jpha.2017.06.001
Public Assessment report; Scientific Discussion. Omlesartan medoxomil / hydrochlorothiazide “Krka”.
DK/H/2521/001-004/DC. 27 March 2017
European Medicines Agency; CHMP assessment report. Ifirmacombi (Irbesartan / hydrochloeo
thiazide). Procedure No. EMEA/H/C/002302
Public Assessment Report; Scientific discussion. Tevaltan comp (Valsartan and hydrochlorothiazide)
DK/H/1524/001-002/DC